Two bipartisan senators press FDA to take a more proactive role in policing prescription drug advertising, citing a surge in misleading direct-to-consumer promotions — for weight-loss treatments.
In a wide-ranging 4/1 address to employees at FDA, commissioner Marty Makary outlines an expansive agenda to accelerate drug approvals, lower costs, and modernize the agency.
Two bipartisan senators press FDA to take a more proactive role in policing prescription drug advertising, citing a surge in misleading direct-to-consumer promotions — for weight-loss treatments.
In a wide-ranging 4/1 address to employees at FDA, commissioner Marty Makary outlines an expansive agenda to accelerate drug approvals, lower costs, and modernize the agency.
President Trump prepares to impose sweeping new tariffs on certain pharmaceutical imports, targeting companies that have not agreed to participate in his administration’s “Most Favored Nation” drug pricing initiative, according to several media reports.
CDRH leaders describe efforts to expand the use of real-world evidence in a range of medical device regulatory activities.
